Cytos Biotechnology to be renamed Kuros Biosciences, names new CEO

8 January 2016
cytosbig

Switzerland-based Cytos Biotechnology (SIX: CYTN) on Friday said the company will be renamed Kuros Biosciences and that its chief executive Christian Itin will be stepping down from his position.

The transition is part of the restructuring ahead of the closing of acquisition of Kuros Biosurgery holding AG which is expected to take place within next few weeks.

Dr Itin will be replaced by Didier Cowling.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology